Eurofarma - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 39

Eurofarma – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Eurofarma - Product Pipeline Review - H2 2011” provides data on the Eurofarma’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Eurofarma’s corporate website, SEC filings, investor presentations and featured press releases, both from Eurofarma and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Eurofarma - Brief Eurofarma overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Eurofarma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Eurofarma with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Eurofarma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Eurofarma’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Eurofarma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Eurofarma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Eurofarma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Eurofarma and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Eurofarma; Eurofarma - Key Therapeutics; Eurofarma - Pipeline Overview and Promising Molecules; Eurofarma - News; Eurofarma - Latest Updates; Eurofarma - Pipeline; Eurofarma - Discontinued/Dormant Projects

List of Tables
List of Figures
Eurofarma Snapshot
Eurofarma Overview
Key Information
Key Facts
Eurofarma – Research and Development Overview
Key Therapeutic Areas
Eurofarma – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Eurofarma – Pipeline Products Glance
Eurofarma – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Eurofarma Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Eurofarma – Drug Profiles
Dexalgen
Product Description
Mechanism of Action
R&D Progress
Diupress
Product Description
Mechanism of Action
R&D Progress
Diurisa
Product Description
Mechanism of Action
R&D Progress
Eszopiclone
Product Description
Mechanism of Action
R&D Progress
Filgrastim
Product Description
Mechanism of Action
R&D Progress
Formoterol + Fluticasone
Product Description
Mechanism of Action
R&D Progress
Glucosamine + Chondroitin
Product Description
Mechanism of Action
R&D Progress
Heptar
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Cisplatin + Fluorouracil + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Cisplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Salmeterol + Fluticasone
Product Description
Mechanism of Action
R&D Progress
Symbicort
Product Description
Mechanism of Action
R&D Progress
Eurofarma – Pipeline Analysis
Eurofarma – Pipeline Products by Therapeutic Class
Eurofarma - Pipeline Products By Target
Eurofarma – Pipeline Products by Route of Administration
Eurofarma – Pipeline Products by Molecule Type
Eurofarma – Recent Pipeline Updates
Eurofarma – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Eurofarma, Deals Summary
Eurofarma, Pharmaceuticals & Healthcare, Deal Details
Acquisition
Eurofarma Acquires Laboratorios Gautier
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Eurofarma – Pipeline by Therapy Area and Indication, H2 2011
Eurofarma – Pipeline by Stage of Development, H2 2011
Eurofarma – Monotherapy Products in Pipeline, H2 2011
Eurofarma – Combination Treatment Modalities in Pipeline, H2 2011
Eurofarma – Phase III, H2 2011
Eurofarma - Phase II, H2 2011
Eurofarma - Pipeline By Therapeutic Class, H2 2011
Eurofarma - Pipeline By Target, H2 2011
Eurofarma – Pipeline By Route of Administration, H2 2011
Eurofarma – Pipeline By Molecule Type, H2 2011
Eurofarma – Recent Pipeline Updates, H2 2011
Eurofarma, Other Locations
Eurofarma, Deals Summary
Eurofarma Acquires Laboratorios Gautier

List of Figures
Eurofarma – Pipeline by Therapy Area and Indication, H2 2011
Eurofarma – Pipeline by Stage of Development, H2 2011
Eurofarma – Monotherapy Products in Pipeline, H2 2011
Eurofarma – Combination Treatment Modalities in Pipeline, H2 2011
Eurofarma – Pipeline By Therapeutic Class, H2 2011
Eurofarma - Pipeline By Target, H2 2011
Eurofarma – Pipeline By Route of Administration, H2 2011
Eurofarma – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Analysis of Google Inc
• Scientific Games Corporation - Company Analysis
• Accenture - Profile - US
• Dell - Profile - US
• HP - Profile - US